Computational-chemistry expert Schrödinger Inc. collaborated with his firm "as a co-founder almost," Morphic Therapeutic Inc. CEO Praveen Tipirneni told BioWorld Today, which should provide "an interesting advantage" in working with crystal structures to design oral integrin-targeting drugs.